AEON Biopharma, Inc. (AEON) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $0.25 (+0.08%), Market cap $0.02B, 52-week low–high $0.53 ~ $1.40.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Financial statements, price targets, institutional (13F) holdings and related news for AEON Biopharma, Inc. are updated in real time on BlackAll Trade.
AEON Biopharma, Inc. trades at $0.25 (+0.08%). Real-time quotes and charts are available on BlackAll Trade.
AEON Biopharma, Inc. has a market cap of about $0.02B.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which